Theragenics Announces Stockholder Approval of Merger Agreement with Juniper
BUFORD, Ga.--(BUSINESS WIRE)-- Theragenics Corporation® (NYS: TGX) (the "Company"), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that the stockholders of the Company voted to approve the previously announced merger agreement providing for a newly formed affiliate of Juniper Investment Company, LLC to acquire all of the outstanding common stock of the Company for $2.20 per share in cash.
Over 96% of the votes cast at today's special meeting were voted in favor of the Merger Agreement, representing approximately 64% of the Company's outstanding common stock as of September 16, 2013, the record date for the special meeting.
Upon the closing of the transaction, the Company's common stock will no longer be publicly traded, and the Company will be a wholly owned subsidiary of an affiliate of Juniper Investment Company, LLC. The Company expects that the transaction will be completed as promptly as practicable, subject to customary closing conditions.
Shortly after the transaction is completed, stockholders of record will receive a letter of transmittal and instructions on how to surrender their shares of the Company's common stock to the paying agent in exchange for payment of the merger consideration. Stockholders of record should wait to receive the letter of transmittal before surrendering their shares.
Forward Looking Statements
Certain matters discussed in this report may be forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections of future company or industry performance based on management's judgment, beliefs, current trends and market conditions. Actual outcomes and results may differ materially from what is expressed, forecasted or implied in any forward-looking statement. Forward-looking statements may be identified by the use of words such as "will," "expects," "intends," "plans," "anticipates," "believes," "seeks," "estimates," and similar expressions. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements included in this document. These include, but are not limited to: (i) consents or approvals required for the transaction may not be obtained, or may delay the transaction or result in the imposition of conditions that could have a material adverse effect on the Company or cause the parties to abandon the transaction; (ii) conditions to the closing of the transaction may not be satisfied; (iii) the outcome of any legal proceedings to the extent initiated against the Company and others following the announcement of the transaction cannot be predicted; (iv) the business of the Company may suffer as a result of uncertainty surrounding the transaction; and (v) the Company may be adversely affected by other economic, business, and/or competitive factors. Other factors that could cause the Company's actual results to differ materially from those expressed or implied are discussed under "Risk Factors" in the Company's most recent annual report on Form 10-K and other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.
Frank Tarallo, CFO &Treasurer
Lisa Rassel, Manager of Investor Relations
800-998-8479 - 770-271-0233
KEYWORDS: United States North America Georgia
The article Theragenics Announces Stockholder Approval of Merger Agreement with Juniper originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.